R-002: Nicotine receptor partial agonists for smoking cessation
| Field | Value |
|---|---|
| Research ID | R-002 |
| Authors | Cahill K, Stevens S, Perera R, Lancaster T |
| Year | 2013 |
| Journal / publisher | Cochrane Database of Systematic Reviews |
| DOI | 10.1002/14651858.CD006103.pub4 |
| PMID | Not reported |
| ISBN | Not reported |
| Research type | Systematic Review |
| Evidence strength | Strong |
| Population | Not reported |
| Intervention | Not reported |
| Comparator | Not reported |
| Last verified | 2026-10-04 |
Main question
How effective are varenicline and cytisine for smoking cessation?
Main findings
Varenicline roughly doubles to triples the odds of quitting compared with placebo in clinical trials. Cytisine also increases quit rates compared with placebo.
Limitations
Trials mostly exclude people with unstable psychiatric conditions; post-marketing safety discussions continue.
Why this record matters
Not reported
Related topics
Quit Smoking Medications; Varenicline; Cytisine
Source
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006103.pub4/full